Abstract Submission
for COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment

Deadline midnight, US Pacific time, Friday 17th of September 2021


Submission Category: Abstracts may be submitted under one of the following categories:

Surveillance of SARS-CoV-2, influenza and RSV
Virus evolution - changes in transmissibility and virulence
Characterisation of antigenic variants - vaccine composition; therapeutic antibodies
Pre-clinical and clinical development of antivirals and immune-therapeutics
Emergence of resistance to antivirals and therapeutic antibodies
Novel strategies for vaccine development
Disease pathogenesis
Non-pharmaceutical prevention strategies
Pandemic preparedness strategies

Publication: Upon submission of an abstract, the author provides consent to publish the abstract on the virtual conferencing platform.

Co-Author Approval: Ensure that all co-authors approve of the abstract submission, publication, and potential presentation. Abstracts cannot be changed or withdrawn after the 17th of September 2021.

Author Disclosure: All abstract authors are required to disclose any conflict of interest.

Changes to Abstract: You are able to edit your abstract until the submission deadline. After the submission deadline, only minor abstract changes (author or institution changes, disclosure or keyword updates) are allowed. The deadline for minor updates and all withdrawals is the 17th of September 2021. Any corrections and/or changes will not be accepted after these dates.

Abstract Receipt Confirmation: You should receive email confirmation within two hours of submitting your abstract. If, after checking your spam folder, you have not received this confirmation then please contact Quad Logic technical support.

Abstract policy, deadlines, notifications, programming, general conference questions, contact isirv Conference secretariat.
Technical support questions related to problems with online abstract submission, contact Quad Logic.


Abstract Preparation: Abstracts must conform exactly to the instructions provided for electronic submission. Abstracts must be submitted in English and all presentations will be in English.

Layout of Submission: Each abstract will need to include the title, background, methods, results and conclusion.

Character Limit: A complete abstract submission will be a maximum of 2,750 characters. This includes the background, methods, tables, figures, results, conclusions and spaces. This does NOT include the authors and institutions.

File Attachment: File attachment is only for additional figures or tables with the content character count taken into consideration. This facility is not used to upload abstracts by pdf.